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Physicochemical characterization and dissolution studies
of acyclovir solid dispersions with Pluronic F127 prepared 
by the kneading method
The dissolution rate of anhydrous acyclovir was improved 
by the preparation of physical mixtures and solid disper-
sions with the non-ionic polymer Pluronic F127 using the 
kneading method at diff erent drug-to-polymer ratios. The 
obtained physical mixtures and solid dispersions were ex-
amined in terms of drug content and possible physical and 
chemical interactions between the drug and polymer using 
FTIR spectral studies, diff erential scanning calorimetry 
and powder X-ray diff raction analysis. The dissolution rate 
of acyclovir was determined using the rotating disk method. 
It was found that the minimal content of the polymer within 
the mixtures needed to increase the dissolution rate of the 
drug was 50 %.
Keywords: acyclovir, Pluronic F127, solid dispersions, physi-
cal mixtures, kneading, dissolution improvement
Acyclovir (ACV) is an antiviral compound used in the treatment of diseases caused 
by the Herpes simplex (type 1) and Varicella zoster viruses (1, 2). Administration of acyclovir 
via the oral route leads to low and variable bioavailability (15–30 %) (3). This classifi es ACV 
as a BCS class III or IV drug with low permeability and high solubility or very low solubi-
lity and permeability (4). Furthermore, multiple administration of large doses of the drug 
required to achieve therapeutic concentration in the blood increases possible side eff ects 
such as nausea, diarrhoea and headaches, resulting in patient non-compliance (5).
ACV forms two hydrates with 3:2 (commercial ACV, form V) and 1:2 (form VI) drug-to-
-water ratios and four anhydrous crystalline forms: two stable under ambient conditions 
(forms I and II) and two metastable high temperature forms (forms III and IV) (6, 7). In this 
work, we use the nomenclature of ACV forms as proposed by Lutker et al. (6). The anhy-
drous form I dissolves relatively slower than the hydrated form V (8). Active ingredients 
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forms (9). Various methods for increasing dissolution of ACV have been described, includ-
ing micronization, nanosuspension, solid dispersions (10), inclusion complex with cyclo-
dextrin (11), co-crystallisation, amorphisation (12) or formulation of microemulsions (10, 
13) and niosomes (5, 14, 15). Dissolution rates of ACV from solid dispersions with urea, 
mannitol and selected polymers were compared to the pure substance (14, 16, 17). In stud-
ies done by Kushwaha et al. (14, 16) the plasma concentration of ACV in rabbits, aft er a 
single dose of a pure substance as a solution and as a solid dispersion, showed signifi -
cantly higher AUC values (5 times) obtained from the latt er.
It was recently shown by our group and other authors that Pluronic F127 can be used 
successfully as a carrier for dissolution rate improvement of poorly water-soluble drugs, 
including simvastatin (18) and ketoconazole (19–22). The aim of this study was to increase 
acyclovir dissolution rate by preparing physical mixtures and solid dispersions of anhy-
drous acyclovir form I (ACV) with Pluronic F127 (PLU).
EXPERIMENTAL
Materials
The acyclovir used in the study was a gift  from Valeant Pharmaceuticals Interna-
tional, Inc., Poland. Pluronic F127 was purchased from Fluka Biochemica (Germany). 
Sodium lauryl sulfate (SLS) was purchased from P. P. H. Stanlab (Poland). The HPLC grade 
methanol was obtained from Chempur (Poland). Finally, potassium bromide and hydro-
chloric acid 37 % were obtained from POCH (Poland). All other chemicals and reagents 
were of analytical grade.
Methods
Preparation of anhydrous form of acyclovir (form I). – Commercially available acyclovir 
(polymorphic form V of ACV) is a 3:2 ACV:water hydrate (6). The anhydrous crystalline 
form of acyclovir (form I) was prepared according to the method described by Lutker et 
al. (6). Ten grams of ACV form V was briefl y dehydrated by heating in an oven at a tem-
perature range from 25 to 180 °C using a heating rate of 5 °C min–1. Aft er cooling, the 
samples were stored in desiccators at room temperature until use. The formation of anhy-
drous crystalline form I of acyclovir was confi rmed by DSC, XRPD and FTIR and it was 
used to formulate physical mixtures and solid dispersions.
Preparation of physical mixtures (PM). – ACV and PLU were weighed accurately and 
mixed in an agate mortar for 10 minutes in order to obtain a homogenous mixture. The 
mass ratios of the mixtures were: 90/10, 80/20, 70/30, 60/40, 50/50, 40/60, 30/70, 20/80 and 
10/90 %. The obtained solid dispersions were sieved through a 315-μm sieve and stored in 
a desiccator (at room temperature) until further analysis.
Preparation of solid dispersions using the kneading method (KN). – Mixtures of ACV and 
PLU were prepared by grinding accurately weighed quantities of each compound in an 
agate mortar with 2 mL of 97 % methanol for 10 minutes. Aft er solvent evaporation, dry 
powder was again triturated in an agate mortar and sieved through a sieve with a mesh 
size of 315 μm. The mass ratios of the mixtures were: 90/10, 80/20, 70/30, 60/40, 50/50, 40/60, 
30/70, 20/80, and 10/90. The obtained solid dispersions were stored in a desiccator at room 
temperature until use.
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Drug content determination. – Ten-mg equivalent of anhydrous ACV in either physical 
mixture or solid dispersion was dissolved in 100 mL of 0.1 mol L–1 HCl. The prepared solu-
tions were diluted in a 1:10 ratio and the drug was determined spectrophotometrically at 
252 nm using a UV-Vis spectrophotometer (Jasco V-650, Japan). The percentage of drug 
loading was calculated for all mixtures.
Diff erential scanning calorimetry (DSC). – The DSC measurement of each mixture was 
performed using a diff erential scanning calorimeter (Mett ler Toledo DSC 25, Switzerland) 
equipped with a heat-fl ow sensor and connected via an interface TA Controller TC 15 to a 
computer. Measurements were taken by STARe soft ware. Samples for DSC measurements 
were sealed in 40-μL standard aluminum crucibles with a single hole punched in the lid. 
An empty pan of the same type was employed as reference. The DSC instrument was 
calibrated using the melting point of indium (156.6 ± 0.3 °C) as a standard. DSC scans of 
each sample were performed at a heating rate of 5 °C min–1 in a temperature range of 25 to 
300 °C. The DSC cell was purged with a stream of dry argon at a rate of 50 mL min–1.
Powder X-ray diff raction analysis (XRPD). – Powder X-ray diff raction patt erns of anhy-
drous ACV, PLU, their physical mixtures and solid dispersions were recorded at room 
temperature using an Ultima IV powder diff ractometer, equipped with a Cross Beam Op-
tics (Rigaku, Japan) with CuKα radiation. The scanning rate of 10° min–1 was applied be-
tween 3 and 60° (2θ).
Fourier transform infrared spectroscopy (FTIR). – FTIR spectra were acquired using an IR 
Affi  nity-1 spectrometer (Shimadzu, Japan) from 4000 to 200 cm–1. Prior to analysis, samples 
were mixed in an agate mortar with KBr powder (spectroscopic grade) and were com-
pressed into a 13-mm disc under the pressure of 10 tons for 1 minute using a hydraulic 
press (Specac Ltd., UK). The KBr spectrum was used as background.
Dissolution studies. – Dissolution studies were carried out for anhydrous ACV, physical 
mixtures and solid dispersions at all drug-to-polymer ratios. The dissolution system was 
fi tt ed with an SR8-PLUS dissolution bath (Hanson, USA) and a 7-channel peristaltic pump. 
The dissolution rate was measured using the pharmacopeial rotating disk method (25). 
ACV (100.0 mg), or an equivalent amount of solid dispersion, was prepared by compress-
ing powder into discs using a hydraulic press (Specac Ltd.) for 1 minute under a compres-
sion force of 1 t using an 8-mm punch. The die was mounted on the stirring drive mecha-
nism and was rotated at 50 rpm. The dissolution test was conducted under sink conditions 
in 1000 mL of distilled water containing 0.5 % SLS at 37 ± 0.5 °C. Samples were collected 
aft er 5, 10, 15 20, 25, 30, 45 and 60 min of the study. The ACV quantity was determined 
spectrophotometrically at 252 nm. The calibration curve was constructed by measuring 
ACV absorbance in 0.5 % SLS solution ranging from 1.6 to 8.0 μg mL–1 (R2 = 0.999).
RESULTS AND DISCUSION
Drug in physical mixtures and solid dispersions
It is of paramount importance in pharmaceutical drug delivery to ensure a uniform 
content of API within the formulations as well as monitoring of possible phase transitions 
of the drug during processing. Acyclovir content within the formulated physical mixtures 
and solid dispersions, in the range of 97.6 to 101.7 % of the weighed amount, was in good 
agreement with expected values. As several solvates and polymorphic forms of ACV had 
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been reported in the literature, careful control over formulation processes and monitoring 
of the fi nal phase of the active pharmaceutical ingredient (API) within the physical mix-
tures and solid dispersions was investigated using DSC, PXRD and FTIR (6–9).
The DSC thermogram of ACV form I (Fig. 1a) shows three thermal eff ects. The fi rst 
endotherm can be assigned to reversible phase transition of ACV form I to ACV form IV 
at 172.9 °C, followed by melting of ACV form IV at 255.1 °C and exothermic decomposition 
at 258.7 °C. Incorporation of ACV in the polymer matrix does not aff ect the onset of the fi rst 
phase transition of ACV form I to ACV form IV in all investigated drug-to-polymer ratios 
of both physical mixtures and solid dispersions (Figs. 1b and c). The magnitude of heat 
(corresponding to the enthalpy of solid-solid phase transition) increases gradually with 
the increasing ACV mass fraction. The second peak, corresponding to the melting of the 
stable anhydrous ACV form IV at 255.1 °C, was generally broader, indicating that complete 
melting took place over a wider temperature range. The broadening of ACV melting peak 
Fig. 1. DSC thermograms of: a) anhydrous ACV and PLU, b) ACV/PLU physical mixtures (PM) and c) 
ACV/PLU solid dispersions obtained by the kneading method (KN).
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results from the increase in the polymer content in physical mixtures or solid dispersions. 
The DSC curve of PLU (Fig. 1a) shows only one endothermic event, associated with its 
melting at 52.6 °C. The DSC thermograms of the studied physical mixtures and solid dis-
persions show only phase transitions of PLU and ACV form I, indicating that mixing of 
both compounds does not aff ect the polymorphic order of ACV and the phase transition 
of either compound.
The DSC data are further corroborated by XRPD and FTIR analysis. The diff raction 
patt ern of ACV used to prepare the formulations can be assigned to the anhydrous ACV 
form I based on characteristic peaks at 8.52, 11.66, 24.07 and 28.74° 2θ. ACV form I can be 
obtained by slow dehydration of the ACV form V, which recrystallizes into monoclinic 
P21/c space group with Z’ = 1, as reported by Lutker et al. (6). Due to the reversible phase 
transition between ACV form I and ACV form V at elevated humidity, it is important to 
assure phase stability during mixing with the polymer. XRPD diff raction patt erns of the 
investigated physical mixtures and solid dispersions show characteristic patt erns of ACV 
form I, indicating stability of the crystalline phase aft er formulation with PLU. Further-
more, two distinct peaks of semicrystalline PLU, at 19.12 and 23.26° 2θ, can be observed. 
All XRPD patt erns of physical mixtures and solid dispersions show superposition of both 
ACV form I and PLU peaks, indicating no changes in the crystalline phase and crystallin-
ity of either material.
Diff erences in the dissolution rate of physical mixtures or solid dispersions may result 
from intermolecular interactions in the solid state between API and polymer (24). Infrared 
spectroscopy is highly sensitive probe to investigate inter- and intra-molecular interac-
tions in the solid state. Furthermore, IR enables to distinguish between the drug polymor-
phic forms due to its sensitivity to structural diff erences arising from distinct hydrogen 
bonding patt erns within diff erent crystalline forms (25). The FTIR spectrum of anhydrous 
ACV form I shows a characteristic N-H vibration region with two peaks at 3433.29 and 
3398.57 cm–1. The peaks for primary amines are present at 3280.92 and 3180.62 cm–1 and the 
peak characteristic of the secondary amines is clearly visible at 3088.03 cm–1. Furthermore, 
the sharp peak at 1629.85 cm–1 represents an N-H bond of primary amines and the peak 
Fig. 2. XRPD patt erns of: a) anhydrous ACV, b) 80/20 (%, m/m) ACV/PLU-PM, c) 80/20 (%, m/m) ACV/
PLU-KN, d) 20/80 (%, m/m) ACV/PLU-PM, e) 20/80 (%, m/m) ACV/PLU-KN, f) PLU.
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Fig. 3. FTIR spectra of: a) anhydrous ACV, f) PLU, and selected solid dispersions: b) 80/20 (%, m/m) 
ACV/PLU-PM, c) 20/80 (%, m/m) ACV/PLU-KN, d) 20/80 (%, m/m) ACV/PLU-PM, e) 20/80 (%, m/m) ACV/
PLU-KN.
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visible at 1695.43 cm−1, the stretching vibration of the –C=O group of API. The occurrence 
of a combination of band patt erns in the wavenumber region of 2000–1650 cm–1 and the 
CH-stretch region of the FTIR spectrum above 3000 cm–1 indicates the presence of an aro-
matic group. The spectrum of Pluronic F127 shows two characteristic absorption peaks at 
1242.16 and 1149.57 cm–1 arising from C-O stretching vibrations (Fig. 3). However, both 
drug and polymer may potentially form multiple hydrogen bonds due to the presence of 
amine and hydroxyl groups in ACV and carbonyl groups in PLU. FTIR spectra of the 
physical mixtures and solid dispersions are superpositions of the spectra of individual 
components. Such results show no interactions between the components aft er formulation 
and indicate chemical stability of the drug and the mixtures obtained aft er processing.
Dissolution studies
The intrinsic dissolution rate (IDR) is of great interest in preformulation research as it 
enables, bett er correlation of in vitro results with in vivo behavior of the drug (26). IDR is 
defi ned as the dissolution rate of a pure compound under the condition of constant surface 
area. IDR was determined according to the equation (27):
 
where                  is the maximum slope in the dissolution curve evaluated at the start of the 
dissolution process, A is the area of the drug disk (cm2), m is the mass (mg), t is the time 
(min). As determination of the dissolution rate in comparison with solubility studies does 
not depend on saturation concentration of API in the medium, it is less sensitive to the 
errors related to possible phase changes within the formulation. Furthermore, physical 
changes of API at the surface exposed to the dissolution medium, including recrystalliza-
tion from the amorphous state or changes in hydration levels, can be easily monitored by 
rapid changes in the slope of the dissolution curve (26–29). Fig. 4 shows the amount of 
anhydrous ACV dissolved from physical mixtures and solid dispersions with PLU in a 0.5 
% SLS solution as a function of time. Results suggest that the dissolution rate of ACV form 
I from physical mixtures and solid dispersions containing more than 60 % (m/m) of PLU is 
higher compared to that of anhydrous ACV form I. Aft er 60 minutes of the test, over 26 % 
of ACV was released from the solid dispersion 10/90 % (m/m) ACV/PLU prepared by the 
kneading method, while at that time only 11 % of pure ACV had dissolved. A decrease in 
dissolution was observed for physical mixtures and solid dispersions containing 60–90 % 
(m/m) of ACV. As the polymer concentration increases, dissolution also increases due to 
enhanced disaggregation and wett ing of ACV particles in the presence of the hydrophilic 
group of the polymer and surface active properties of PLU (21). In the dissolution medium, 
the hydrophilic polymer undergoes rapid dissolution, maintaining a high concentration in 
the diff usion layer of the drug and thus improving the dissolution of the drug in this 
layer and thereby increasing the dissolution rate of the substance. Furthermore, formation 
of PLU micelles in dissolution medium may also lead to increased dissolution of ACV, 
since it can be partly entrapped within the hydrophobic core of the micelles (30). I DR of 
anhydrous ACV, its physical mixtures and solid dispersions with PLU and the linear rela-
tionship between the amount of the dissolved drug and time are given in Table I. These 
results further indicate no phase transformation of ACV form I to its hydrated form (ACV 
form V) within the time of the dissolution studies, since there is no change in the slope of 
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Fig. 4. The dissolution profi les of: a) physical mixtures and b) solid dispersions in 0.5 % sodium lauryl 
sulfate aqueous solution.
Table I. IDR of ACV and its mixtures, solid dispersions with PLU and the corresponding ratios
Formulation IDR (mg cm–2 min–1) R2 IDR ratio formulation/ACV
10/90 (%, m/m) ACV/PLUPM 0.9534 ± 0.0005 0.9693 2.30
20/80 (%, m/m) ACV/PLUPM 0.6502 ± 0.0033 0.9943 1.57
30/70 (%, m/m) ACV/PLUPM 0.5699 ± 0.0021 0.9995 1.38
40/60 (%, m/m) ACV/PLUPM 0.4976 ± 0.0135 0.9995 1.20
10/90 (%, m/m) ACV/PLUKN 0.8883 ± 0.0014 0.9989 2.14
20/80 (%, m/m) ACV/PLUKN 0.7995 ± 0.0023 0.9993 1.93
30/70 (%, m/m) ACV/PLUKN 0.6006 ± 0.0067 0.9995 1.45
40/60 (%, m/m) ACV/PLUKN 0.5100 ± 0.0325 0.9987 1.23
ACV 0.4144 ± 0.0623 0.9733 –
Mean ± SD (n = 3).
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CONCLUSIONS
In this paper, we have demonstrated the application and evaluation of the non-ionic 
polymer Pluronic F127 for the preparation of physical mixtures and solid dispersions with 
acyclovir. It was found that the minimal content of the polymer within the mixtures need-
ed to increase the dissolution rate of the drug is 50 %. The phase of ACV form I did not 
change during the preparation of physical mixtures or solid dispersions, which was prov-
en by DSC, FTIR and XRPD. This indicates successful incorporation of ACV form I within 
the polymer matrix without polymorphic transitions of API.
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